The first synthesis of siderophore conjugates of two macrolide antibiotics, spiramycin 1 and neospiramycin 2, which are unable to penetrate the outer membrane of Gramnegative bacteria are described. These novel conjugates were prepared by regioselective acylation of a hydroxyl function of 1 and 2 with a dihydroxybenzoic Fe (III) complexing ligand linked via a carboxyl group containing spacer to the macrolide antibiotics. The preliminary biological evaluation of these novel conjugates under standard and iron depleted conditions has shown that their antibacterial activity was comparable to that of spiramycin 1 and neospiramycin 2.
Infections due to various bacteria and viruses are a major cause of mortality worldwide. It has been demonstrated that some of the bacteria involved in these infections produce iron (III) complexing compounds of low molecular weight called siderophores, which contribute to the virulence by depriving the host of iron1).
Bacteria are gradually becoming more and more resistant to antibacterial agents. Thus antibacterials with increased activity are constantly needed. Antibiotics such as macrolides are unable to penetrate the outer membrane of Gram-negative bacteria while being active on the ribosomal target.
Recently, several groups have demonstrated that the antibiotics greatly improves their biological activity against Gram-negative bacteria2,3). This astute application was inspired by the existence of a few natural compounds like the ferrimycins4) and the albomycins5) which combine strong iron chelators with an antibiotic moiety within the same molecular assembly.
These results and our own interest in this field6) encouraged us to apply this approach (the "Trojan horse concept"3)-Scheme 1) to macrolide antibiotics like spiramycin 1 and neospiramycin 2.
Chemistry
Spiramycin 1 is a natural 16-membered macrolide produced by Streptomyces ambofaciens7). While the hydrogenation of the two conjugated double bonds does not seriously affect the biological activity of 1 and 28), the aldehyde function and the presence of the aminosugars mycaminose and forosamine are essential for their antibacterial activity (Scheme 2).
Previous studies have shown that the acylation of 1 at position 4" does not alter significantly its activity against bacteria8 We chose various natural amino acids as spacers to link an hydroxyl group of the antibiotic to a dihydroxybenzoic acid for two major reasons: the eventual control of the release by enzymatic hydrolysis in vivo of the spacer and the absence of any forseeable toxicity of their metabolites.
Thus, several amino acids were protected as benzyl alcohol and p-toluene sulfonic acid in toluene. Reaction with 2, 3-dioxosulfinyl benzoyl chloride 611) (which can be easily prepared from dihydroxybenzoic acid and was realized with classical coupling reagents (DCC or CDI) using either 2'-acetyl-spiramycin 3a to give the 4"-O-acylated derivative 3b, or on spiramycin 1 leading to 2'-acylated compounds 3c, 3g, 3h, 3i. Reaction of neospiramycin 2 with 10c under the same conditions furnished a 2',4"-diacylated derivative 3j. The major difficulty encountered with these products was their final purification: chromatography over silicagel gave extremely poor yields of recovered material (<3% AUG. 1998 to note that compounds 3h and 3i which are acylated in position 2' of the mycarose unit of spiramycin with the spacer-ligand units 10a and 10d, show similar MICs when compared to the parent compound 1. Under ferric stress conditions, when bacterial growth was allowed (Table 2) , no significiant decrease of the MICs was observed. A few hypotheses can be proposed in order to explain these results:
The adducts may be enzymatically hydrolyzed before reaching their target within the bacterial cell.
The receptor site at the surface of the bacterial cell wall may not recognize mono-or dicatechols.
Finally, even if these "Trojan horses" are recognized by the receptors, their mere size (MW close to 3000, see Exp. Part) may not allow them to pass through the membrane channels.
The synthesis of tricatechol and trihydroxamate conjugates of spiramycin 1 of lower molecular weight, less prone to enzymatic hydrolysis by introducing steric hindrance around the ester linkage, is in due course in our laboratory. NMR spectra were recorded on BRUKER instruments: AM 200, AM 250 or AM 400 at respectively 200MHz, 250MHz or 400MHz for 1H and 50MHz, 62MHz or 100MHz for 13C with deuterated chloroform as internal reference (7.24ppm for 1H and 77ppm for 13C) .
MS
For compounds with a molecular weight under 700 mass units, a Riber-Mag R-10-10 apparatus was used in the direct introduction mode with chemical ionization by NH3. The higher molecular weights were analyzed by ES-MS or FAB-MS on a Platform (VG Fisons) quadrupole instrument. Calibration was performed using a cesium iodide solution (10ng/ml) for the weight range samples were dissolved in methanol and diluted in 0.2% formic acid solution (pH=3)/acetonitrile (50:50) with a concentration of 20 to 100ng/ml. . THE and ether were freshly distilled over benzophenone-sodium just before use. Toluene was distilled over Na, pyridine over KOH and methylene chloride over P2O5. All the manipulations were effected under argon atmosphere.
2, 3-Diacetoxybenzoic
Acid 5 A suspension of 2, 3-dihydroxybenzoic acid (5g; 32.5 mmol) in 7ml of acetic anhydride was stirred at room temperature and two drops of concentrated sulfuric acid were added. After five minutes, a precipitate formed, 35ml of anhydrous ether were added and the solution was stirred for 12 hours at room temperature. Extraction with CH2Cl2, washing with cold water, drying over MgSO4 and evaporation of the solvent yielded 7.04g of the title compound (91% 96, 25.88, 28.35, 33.50, 39.44, 125.32, 125.98, 126.21, 130.23, 139.64, 142.55, 165.28, 167.90, 168.08, 177.93; Anal Calcd for C17H21NO7: C 58.10, H 6.03, N 3.99. Found: C 56.55, H 6.29, N 3.32. 10c: C16H19NO7, MW 337.33; Yield 90%; 1H NMR s), 2.33 (3H, s), 4.77 (1H, dd), 6.9 (1H, d), 7.3 (1H, m), 20.34, 20.50, 31.0, 57.38, 126.27, 126.58, 127.21, 129.14, 139.88, 142.63, 164.90, 168.05, 168.14, 175.19 
238mg of compound 10a (0.73 mmol; 1.2 equiv) were dissolved in 10ml of CH2Cl2 at room temperature and 152mg of DCC (0.73 mmol; 1.2 equiv) and catalytic amount of PPY (4-pyrrolidinopyridine)14) were added and stirred for one hour. 544mg (0.61 mmol; 1 equiv) of 2'-O-acetyl spiramycin 3a and the mixture was stirred overnight. The precipitate of dicyclohexylurea was filtered. The filtrate was washed with water and the organic layer was dried over MgSO4. The solvent was evaporated and the crude reaction product was chro- 2'-O-(3, 4-Dihydroxybenzoyl)spiramycin 3d 230mg (10 mmol) of sodium was added under argon 960mg (10 mmol) of guanidine hydrochloride were added and the solution was stirred during a few minutes and the precipitate of NaCl was filtered. 130mg of 2'-O-(3, 4-diacetoxybenzoyl)spiramycin 3c were dissolved in 5ml EtOH-CH2Cl2 9/1. 150ml of the above solution was introduced (1 equiv guanidine) and the solution was stirred 15 minutes at room temperature. Then, the solvent was evaporated, the product was dissolved in CH2Cl2
and washed with water. After drying and evaporation of the solution, 119mg of compound 3d were obtained (99%). C50H78N2O17, MW 979.18; 1H NMR (400MHz, Iron Complex 3e 343mg (0.35 mmol) of 2'-O-(3, 4-dihydroxybenzoyl)-spiramycin 3d was dissolved in 10ml anhydrous MeOH, 43mg (0.12mmol) Fe(acac)3 and 0.1ml of triethylamine.
The reaction mixture was stirred 3 hours at room temperature. The crude product was filtered on Sephadex LH-20 to yield 230mg of complex 3e (33%).
C150H228N6O51Fe, MW 2987.34; ES-MS m/z 2984
